City
Epaper

EU authorizes AstraZeneca/Oxford COVID-19 vaccine

By IANS | Published: January 30, 2021 1:46 PM

Brussels, Jan 30 The European Commission has granted conditional marketing authorization for the Covid-19 vaccine developed by British ...

Open in App

Brussels, Jan 30 The European Commission has granted conditional marketing authorization for the Covid-19 vaccine developed by British company AstraZeneca and Oxford University, although the bloc seems unlikely to get the amount of doses as agreed at the moment.

"Securing safe vaccines for Europeans is our utmost priority. With the AstraZeneca vaccine now authorized, 400 million additional doses will be available in Europe," European Commission President Ursula von der Leyen said on Friday.

Von der Leyen said that she expected AstraZeneca to deliver the doses as agreed so that Europeans can be vaccinated as soon as possible, reports Xinhua news agency.

"We will continue doing all we can to secure more vaccines for Europeans, our neighbors and our partners worldwide."

The European Union has been squabbling with the British company over the latter's announcement that it may deliver considerably fewer doses than promised for the first quarter.

The bloc published the contract with AstraZeneca on Friday, and meanwhile launched a transparency measure to regulate vaccines export from the union.

This is the third Covid-19 vaccine authorized in the EU, after Pfizer/BioNTech and Moderna vaccines were given the greenlights in late December and early January.

The authorization on Friday was granted hours after the European Medicines Agency (EMA) issued a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine.

Combined results from four clinical trials in the UK, Brazil and South Africa, involving around 24,000 people, showed that the vaccine was safe and effective in preventing Covid-19 in people from 18 years of age, according to the EMA.

Based on data relating to patients who received standard doses followed by second standard doses, the conclusion was drawn that the vaccine demonstrated nearly 60 percent efficacy in the clinical trials, it added.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: ukEuropean CommissionBrusselsAstrazenecaUnion minister of healthUnion minister for healthJustice commissionState health directorateAstrazeneca plc.The european commission
Open in App

Related Stories

InternationalAstraZeneca Withdraws COVID-19 Vaccine Globally Days After Side Effect Row, Firm Says Decision ‘Commercial’

NationalCovaxin-Developer Bharat Biotech Amid Reports on AstraZeneca Vaccine, Says ‘Safety Is Primary Focus for All Our Vaccines’

NationalCovishield Vaccine Side Effect: Serum Institute Faces Legal Action As Parents of Deceased Girls Prepare Lawsuit

NationalPM Modi's Photo Removed from COVID-19 Vaccination Certificates, Know The Reason

NationalCovishield Vaccine Side Effects: Plea Filed in Supreme Court To Examine Adverse Effects of AstraZeneca’s COVID-19 Vaccine

Health Realted Stories

HealthHow to Boost Your Vitamin B-12 Intake: Top Foods to Include in Your Diet

HealthPressure to be perfect raising burnout in parents, anxiety in children: Study

HealthWhy is India the thalassemia capital of the world?

HealthWhy has AstraZeneca recalled Covid-19 vaccine

HealthSamsung’s affiliate acquires French AI medtech startup Sonio